Add like
Add dislike
Add to saved papers

Atrial vulnerability is a major mechanism of paroxysmal atrial fibrillation in patients with Wolff-Parkinson-White syndrome.

Atrioventricular re-entrant tachycardia is the most common form of tachycardia in patients with Wolff-Parkinson-White (WPW) syndrome where one or more accessory pathways are present between atria and ventricles. Paroxysmal atrial fibrillation (PAF) is also a relatively common form of tachycardia in these patients. The mechanisms of PAF in patients with WPW syndrome are not completely understood. Previous studies have mainly focused on the role of accessory pathways in the development of PAF. However, up to 24% of patients still experience PAF after successful ablation of accessory pathways by surgical incision or radiofrequency catheter ablation techniques. We hypothesized that there are two primary mechanisms involved in the pathogenesis of PAF in patients with WPW syndrome. One is related to the accessory pathways that predispose the atria to fibrillation; the other is increased atrial vulnerability that is independent of the accessory pathways. Clarification of these mechanisms is critical in developing more effective means for the prevention or treatment of PAF in patients with WPW syndrome.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app